Advertisement
NeurAxis Inc. (NRXS)
NASDAQ: NRXS
· Real-Time Price · USD
2.27
-0.03 (-1.30%)
At close: Apr 29, 2025, 2:47 PM
Company Description
NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States.
It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics.
The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022.
The company was founded in 2011 and is headquartered in Carmel, Indiana.
NeurAxis Inc.
| Country | United States |
| IPO Date | Aug 9, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 21 |
| CEO | Brian Carrico |
Advertisement
Contact Details
Address: 11550 North Meridian Street Carmel, Indiana United States | |
| Website | https://neuraxis.com |
Stock Details
| Ticker Symbol | NRXS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001933567 |
| CUSIP Number | 64134X201 |
| ISIN Number | US64134X2018 |
| Employer ID | 45-5079684 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Brian Carrico | President, Chief Executive Officer & Director |
| Timothy Robert Henrichs | Chief Financial Officer |
| Dr. Adrian Miranda | Senior Vice President of Science & Technology and Chief Medical Officer |
| Dr. Christopher Robin Brown D.D.S. | Founder, Director of Innovation & Director |
| Dr. Thomas Carrico | Chief Regulatory Officer and Compliance & Privacy Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 23, 2025 | 4 | Filing |
| Apr 14, 2025 | DEFA14A | Filing |
| Apr 14, 2025 | DEF 14A | Filing |
| Apr 04, 2025 | ARS | Filing |
| Apr 04, 2025 | PRE 14A | Filing |
| Mar 20, 2025 | 10-K | Annual Report |
| Feb 12, 2025 | 424B3 | Filing |
| Feb 05, 2025 | S-3/A | [Amend] Filing |
| Jan 08, 2025 | 8-K | Current Report |
| Dec 13, 2024 | S-3 | Filing |